Scholarlink

Purpose <p>To evaluate associations between psychiatric disorders, psychotropic medication use, and retinal vascular occlusion (RAO and RVO) risk using a large real-world database.</p> Methods <p>This retrospective cohort study used the TriNetX Research Network (~ 149&#xa0;million patients). Psychiatric patients were identified via ICD-10 codes and grouped into three cohorts: (1) psychiatric disorders without pharmacologic treatment versus matched healthy controls, (2) medicated versus unmedicated psychiatric patients, and (3) single-class psychotropic medication users versus matched untreated patients. Extensive exclusions minimized confounding. Cohorts were propensity score–matched for demographic and clinical factors. The primary outcome was retinal occlusion within one year of treatment initiation.</p> Results <p>Among 3,389,889 matched pairs, psychiatric disorders without medication were not associated with increased RO risk compared with controls (HR 0.97, 95% CI 0.87–1.07, <i>p</i> = 0.49). In contrast, among 2,990,601 matched pairs, psychotropic medication use was associated with a modest increase in RO risk (HR 1.20, 95% CI 1.09–1.33, <i>p</i> &lt; 0.001). Class-specific analyses demonstrated a small but statistically significant association for selective serotonin reuptake inhibitors (SSRIs) (HR 1.17, 95% CI 1.03–1.32, <i>p</i> = 0.013), while no significant associations were observed for other medication classes. Patients who developed RO were older and had a higher burden of vascular comorbidities, including hypertension, diabetes, hyperlipidemia, and obstructive sleep apnea.</p> Conclusions <p>Psychiatric disorders alone were not associated with increased RO risk, whereas psychotropic medications, particularly SSRIs, showed a modest increase. Despite low absolute incidence, medication exposure may contribute, warranting cardiovascular risk assessment and ophthalmologic monitoring.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations between psychiatric disorders and medication use, and retinal occlusion: a large-scale retrospective cohort study

  • 期刊论文

  • 发表日期：

    2026年6月29日

查看全文
  • Elham Sadeghi,
  • Michael Kozlov,
  • Nasiq Hasan,
  • Shreyaa Rohindra Lall,
  • Jay Chhablani

摘要

Purpose

To evaluate associations between psychiatric disorders, psychotropic medication use, and retinal vascular occlusion (RAO and RVO) risk using a large real-world database.

Methods

This retrospective cohort study used the TriNetX Research Network (~ 149 million patients). Psychiatric patients were identified via ICD-10 codes and grouped into three cohorts: (1) psychiatric disorders without pharmacologic treatment versus matched healthy controls, (2) medicated versus unmedicated psychiatric patients, and (3) single-class psychotropic medication users versus matched untreated patients. Extensive exclusions minimized confounding. Cohorts were propensity score–matched for demographic and clinical factors. The primary outcome was retinal occlusion within one year of treatment initiation.

Results

Among 3,389,889 matched pairs, psychiatric disorders without medication were not associated with increased RO risk compared with controls (HR 0.97, 95% CI 0.87–1.07, p = 0.49). In contrast, among 2,990,601 matched pairs, psychotropic medication use was associated with a modest increase in RO risk (HR 1.20, 95% CI 1.09–1.33, p < 0.001). Class-specific analyses demonstrated a small but statistically significant association for selective serotonin reuptake inhibitors (SSRIs) (HR 1.17, 95% CI 1.03–1.32, p = 0.013), while no significant associations were observed for other medication classes. Patients who developed RO were older and had a higher burden of vascular comorbidities, including hypertension, diabetes, hyperlipidemia, and obstructive sleep apnea.

Conclusions

Psychiatric disorders alone were not associated with increased RO risk, whereas psychotropic medications, particularly SSRIs, showed a modest increase. Despite low absolute incidence, medication exposure may contribute, warranting cardiovascular risk assessment and ophthalmologic monitoring.